|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cirrhotic portal hypertension: From pathophysiology to novel therapeutics显示文摘Portal hypertension and bleeding from gastroesophageal varices is the major cause of morbidity and mortality in patients with cirrhosis. Portal hypertension is initiated by increased intrahepatic vascular resistance and a hyperdynamic circulatory state. The latter is characterized by a high cardiac output, increased total blood volume and splanchnic vasodilatation, resulting in increased mesenteric blood flow. Pharmacological manipulation of cirrhotic portal hypertension targets both the splanchnic and hepatic vascular beds. Drugs such as angiotensin converting enzyme inhibitors and angiotensin Ⅱ type receptor 1 blockers, which target the components of the classical renin angiotensin system(RAS), are expected to reduce intrahepatic vascular tone by reducing extracellular matrix deposition and vasoactivity of contractile cells and thereby improve portal hypertension. However, these drugs have been shown to produce significant offtarget effects such as systemic hypotension and renal failure. Therefore, the current pharmacological mainstay in clinical practice to prevent variceal bleeding and improving patient survival by reducing portal pressure is non-selective-blockers(NSBBs). These NSBBs work by reducing cardiac output and splanchnic vasodilatation but most patients do not achieve an optimal therapeutic response and a significant proportion of patients are unable to tolerate these drugs.Although statins, used alone or in combination with NSBBs, have been shown to improve portal pressure and overall mortality in cirrhotic patients, further randomized clinical trials are warranted involving larger patient populations with clear clinical end points. On the other hand, recent findings from studies that have investigated the potential use of the blockers of the components of the alternate RAS provided compelling evidence that could lead to the development of drugs targeting the splanchnic vascular bed to inhibit splanchnic vasodilatation in portal hypertension. This review outlines the mechanisms related to the pathogenesis of portal hypertension and attempts to provide an update on currently available therapeutic approaches in the management of portal hypertension with special emphasis on how the alternate RAS could be manipulated in our search for development of safe, specific and effective novel therapies to treat portal hypertension in cirrhosis. | Lakmie S Gunarathne Harinda Rajapaksha Nicholas Shackel Peter W Angus Chandana B Herath | 2020 | World Journal of Gastroenterology2020，26，40： | 24 |
| 2 | Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease显示文摘AIM: To determine characteristics and prognosticpredictors of patients with hepatocellular carcinoma(HCC) in association with non-alcoholic fatty liver disease(NAFLD).METHODS: We reviewed the records of all patients with NAFLD associated HCC between 2000 and 2012. Data collected included demographics; histology; presence or absence of cirrhosis, size and number of HCC, alpha-fetoprotein, body mass index(BMI), and the presence of diabetes, hypertension, or dyslipidaemia.RESULTS: Fifty-four patients with NAFLD associated HCC were identified. Mean age was 64 years with 87% male. Fifteen percent(8/54) were not cirrhotic. 11%, 24% and 50% had a BMI of < 25 kg/m2, 25-29 kg/m2 and ≥ 30 kg/m2 respectively. Fifty-nine percent were diabetic, 44% hypertensive and 26% hyperlipidaemic. Thirty-four percent of the patients had ≤ 1 of these risk factors. Non-cirrhotics had a significantly larger mean tumour diameter at diagnosis than cirrhotics(P = 0.041). Multivariate analysis did not identify any other patient characteristics that predicted the size or number of HCC.CONCLUSION: HCC can develop in NAFLD without cirrhosis. At diagnosis such tumours are larger than those in cirrhotics, conferring a poorer prognosis. | Christopher Leung Sern Wei Yeoh Desmond Patrick Shara Ket Kaye Marion Paul Gow Peter W Angus | 2015 | World Journal of Gastroenterology2015，21，4： | 24 |
| 3 | Intrahepatic cholestasis of pregnancy:When should you look further?显示文摘Pruritis with abnormal liver function tests is the classical presentation of intrahepatic cholestasis of pregnancy(ICP),a condition associated with significant fetal complications.Although the etiology of ICP is unclear in many cases,certain features of the clinical presentation should alert the practitioner to the possibility of an underlying metabolic defect, which may not only affect subsequent pregnancies, but may be an indicator of more serious subsequent liver disease.We report a kindred of Anglo-Celtic descent,among whom many members present with ICP,gallstones or cholestasis related to use of oral contraception.Genetic studies revealed a novel mutation in the ABCB4 gene,which codes for a phospholipid transport protein.The clinical significance of this mutation and the importance of identifying such patients are discussed. | Winita Hardikar Shivani Kansal Ronald P J Oude Elferink Peter Angus | 2009 | World Journal of Gastroenterology2009，15，9： | 22 |
| 4 | Therapeutic potential of targeting the renin angiotensin system in portal hypertension显示文摘Portal hypertension is responsible for the bulk of the morbidity and mortality in patients with cirrhosis.Drug therapy to reduce portal pressure involves targeting two vascular beds.The first approach is to reduce intra hepatic vascular tone induced by the activity of powerful vasocontrictors such as angiotensin Ⅱ,endothelin-1 and the sympathetic system and mediated via contraction of perisinusoidal myofibroblasts and pervascular smooth muscle cells.The second approach is to reduce mesenteric and portal blood flow.Non-selective b-blockers are widely used and have been shown to prolong patient survival and reduce oesophageal variceal bleeding in advanced cirrhosis.However many patients are unable to tolerate these drugs and they are ineffective in a significant proportion of patients.Unfortunately there are no other drug therapies that have proven efficacy in the treatment of portal hypertension and prevention of variceal bleeding.This review briefly outlines current therapeutic approaches to themanagement of portal hypertension,and the evidence supporting the role of the renin angiotensin system(RAS) and the use of RAS blockers in this condition.It will also outline recent advances in RAS research that could lead to the development of new treatments focusing in particular on the recently discovered 'alternate axis' of the RAS. | Chandana B Herath Josephine A Grace Peter W Angus | 2013 | World Journal of Gastrointestinal Pathophysiology2013，4，1： | 9 |
| 5 | Large-area nanopatterned graphene for ultrasensitive gas sensing显示文摘 | Alberto Cagliani David Micheal Angus Mackenzie Lisa Katharina Tschammer Filippo Pizzocchero Kristoffer Almdal Peter Boggild | 2014 | Nano Research2014，7，5： | 7 |
| 6 | Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease显示文摘AIM To determine if manipulation of dietary advanced glycation end product(AGE), intake affects nonalcoholic fatty liver disease(NAFLD) progression and whether these effects are mediated via RAGE. METHODS Male C57Bl6 mice were fed a high fat, high fructose, high cholesterol(HFHC) diet for 33 wk and compared with animals on normal chow. A third group were given a HFHC diet that was high in AGEs. Another group was given a HFHC diet that was marinated in vinegar to prevent the formation of AGEs. In a second experiment, RAGE KO animals were fed a HFHC diet or a high AGE HFHC diet and compared with wildtype controls. Hepatic biochemistry, histology, picrosirius red morphometry and hepatic mR NA were determined. RESULTS Long-term consumption of the HFHC diet generated significant steatohepatitis and fibrosis after 33 wk. In this model, hepatic 4-hydroxynonenal content(a marker of chronic oxidative stress), hepatocyte ballooning, picrosirius red staining, α-smooth muscle actin and collagen type 1A gene expression were all significantly increased. Increasing the AGE content of the HFHC diet by baking further increased these markers of liver damage, but this was abrogated by pre-marination in acetic acid. In response to the HFHC diet, RAGE-/-animals developed NASH of similar severity to RAGE+/+ animals but were protected from the additional harmful effects of the high AGE containing diet. Studies in isolated Kupffer cells showed that AGEs increase cell proliferation and oxidative stress, providing a likely mechanism through which these compounds contribute to liver injury. CONCLUSION In the HFHC model of NAFLD, manipulation of dietary AGEs modulates liver injury, inflammation, and liver fibrosis via a RAGE dependent pathway. This suggests that pharmacological and dietary strategies targeting the AGE/RAGE pathway could slow the progression of NAFLD. | Christopher Leung Chandana B Herath Zhiyuan Jia Sof Andrikopoulos Bronwyn E Brown Michael J Davies Leni R Rivera John B Furness Josephine M Forbes Peter W Angus | 2016 | World Journal of Gastroenterology2016，22，35： | 7 |
| 7 | Solvent Extraction Developments in Southern Africa显示文摘The largest solvent-extraction plant in the world at the time, the Nchanga Copper Operation, was in Zambia. The first commercial process using solvent extraction for the refining of the platinum-group met-als was in South Africa. More recently, the Southern African region has seen the implementation of solvent extraction for other base metals, precious metals, and specialty metals. These include the world firsts of primary production of zinc at Skorpion Zinc in Namibia and the large-scale refining of gold by Harmony Gold in South Africa. Several other flowsheets that use solvent-extraction technology are currently under com-missioning, development, or feasibility study for implementation in this part of the world, including those for the recovery of copper, cobalt, nickel, tantalum, and niobium. | Peter M. Cole Kathryn C. Sole Angus M. Feather | 2006 | Tsinghua Science and Technology2006，11，2： | 4 |
| 8 | Hepatopulmonary syndrome: Update on recent advances in pathophysiology, investigation, and treatment显示文摘 | Josephine A Grace Peter W Angus | 2013 | J Gastroenterol Hepatol2013，，2： | 2 |
| 9 | <ce:link locator='fx1'/> Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation显示文摘 | Edward J. Gane Peter W. Angus Simone Strasser Darrell H.G. Crawford John Ring Gary P. Jeffrey Geoffrey W. McCaughan | 2007 | Gastroenterology2007，，3： | 2 |
| 10 | Consensus Guidelines for the Management of Postoperative Nausea and Vomiting显示文摘 | Tong J. Gan Pierre Diemunsch Ashraf S. Habib Anthony Kovac Peter Kranke Tricia A. Meyer Mehernoor Watcha Frances Chung Shane Angus Christian C. Apfel Sergio D. Bergese Keith A. Candiotti Matthew TV Chan Peter J. Davis Vallire D. Hooper Sandhya Lagoo-Deena | 2014 | Anesthesia & Analgesia2014，，： | 2 |
| 11 | Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation显示文摘 | Edward J. Gane Peter W. Angus Simone Strasser Darrell H.G. Crawford John Ring Gary P. Jeffrey Geoffrey W. McCaughan | 2007 | Gastroenterology2007，，3： | 1 |
| 12 | Electron diffraction based techniques in scanning electron microscopy of bulk matericals 显示文摘 | Angus J Wilkinson Peter B Hirsch | 1997 | Micron1997，28，4： | 1 |
| 13 | Develop a Value-Centered Proposal for Assessing Project Suecess显示文摘 | Angus G Yu Peter D Flett | 2005 | International Journal of Project Management2005，，23： | 1 |
| 14 | Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C显示文摘 | Tom W. Chu Rohit Kulkarni Edward J. Gane Stuart K. Roberts Catherine Stedman Peter W. Angus Brett Ritchie Xiao-Yu Lu David Ipe Uri Lopatin Soren Germer Victor A. Iglesias Robert Elston Patrick F. Smith Nancy S. Shulman | 2012 | Gastroenterology2012，，4： | 1 |
| 15 | Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial显示文摘 | Edward J Gane Stuart K Roberts Catherine AM Stedman Peter W Angus Brett Ritchie Rob Elston David Ipe Peter N Morcos Linda Baher Isabel Najera Tom Chu Uri Lopatin M Michelle Berrey William Bradford Mark Laughlin Nancy S Shulman Patrick F Smith | 2010 | The Lancet2010，，9751： | 1 |
| 16 | Lumbar Repositioning Deficit in a Specific Low Back Pain Population显示文摘 | Peter B. O’Sullivan Angus Burnett Alexander N. Floyd Kristen Gadsdon Julia Logiudice Daniel Miller Hilary Quirke | 2003 | Spine2003，，10： | 1 |
| 17 | Current therapies and novel approaches for biliary diseases显示文摘Chronic liver diseases that inevitably lead to hepatic fibrosis, cirrhosis and/or hepatocellular carcinoma have become a major cause of illness and death worldwide. Among them, cholangiopathies or cholestatic liver diseases comprise a large group of conditions in which injury is primarily focused on the biliary system. These include congenital diseases(such as biliary atresia and cystic fibrosis), acquired diseases(such as primary sclerosing cholangitis and primary biliary cirrhosis), and those that arise from secondary damage to the biliary tree from obstruction, cholangitis or ischaemia. These conditions are associated with a specific pattern of chronic liver injury centered on damaged bile ducts that drive the development of peribiliary fibrosis and, ultimately, biliary cirrhosis and liver failure. For most, there is no established medical therapy and, hence, these diseases remain one of the most important indications for liver transplantation.As a result, there is a major need to develop new therapies that can prevent the development of chronic biliary injury and fibrosis. This mini-review briefly discusses the pathophysiology of liver fibrosis and its progression to cirrhosis.We make a special emphasis on biliary fibrosis and current therapeutic options,such as angiotensin converting enzyme-2(known as ACE2) over-expression in the diseased liver as a novel potential therapy to treat this condition. | Indu G Rajapaksha Peter W Angus Chandana B Herath | 2019 | World Journal of Gastrointestinal Pathophysiology2019，10，1： | 1 |
| 18 | Purification and immunological identification of metallothioneins 1 and 2 from Arabidopsis thaliana显示文摘 | Angus Murphy Zhou jianmin Peter B | 1997 | Plant Physiol1997，113，： | 1 |
| 19 | Evaluation of the Flexion Relaxation Phenomenon of the Trunk Muscles in Sitting 显示文摘 | Peter O Sullivan Wim Dankaerts Angus Burnett | 2010 | Spine2010，31，17： | 1 |
| 20 | Purification and im-munological identification of metallothioneins 1 and 2 from Arabidopsis thaliana显示文摘 | Angus M Zhou J M Peter B | 1997 | Plant Physiol1997，113，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员